The registry is primarily designed to assess outcome, efficacy and residual safety aspects of CRT based on long-term data from an unselected, real-life clinical set-up. Moreover, the observation of the patient status should help to find possible predictors for HF events and to identify areas of improvement for CRT and for CRT device settings.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of cardiovascular adverse events
Timeframe: throughout study duration, average of 3.5 years; annual evaluations
Number of patient deaths
Timeframe: throughout study duration, average of 3.5 years; annual evaluations
Number of all cause hospitalization
Timeframe: throughout study duration, average of 3.5 years; annual evaluations
Number of patients with worsening of heart failure events
Timeframe: throughout study duration, average of 3.5 years; annual evaluations
Number of patients with cerebrovascular events
Timeframe: throughout study duration, average of 3.5 years; annual evaluations
Number of all adverse device effects
Timeframe: throughout study duration, average of 3.5 years; annual evaluations
Number of all device deficiencies
Timeframe: throughout study duration, average of 3.5 years; annual evaluations
Assessment of patients benefit from CRT
Timeframe: throughout study duration, average of 3.5 years; annual evaluations
Number of patient deaths with cardiovascular cause
Timeframe: throughout study duration, average of 3.5 years; annual evaluations
Documentation of LVEF
Timeframe: throughout study duration, average of 3.5 years; annual evaluations
Documentation of LVESV
Timeframe: throughout study duration, average of 3.5 years; annual evaluations